The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

@article{Kulkarni2012TheHR,
  title={The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.},
  author={Rima Kulkarni and Kerim Babaoglu and Eric B Lansdon and Laurence T Rimsky and Veerle van Eygen and Gaston Picchio and Evguenia S. Svarovskaia and Michael D. Miller and Kirsten Lofgren White},
  journal={Journal of acquired immune deficiency syndromes},
  year={2012},
  volume={59 1},
  pages={47-54}
}
BACKGROUND The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance pattern involving the NNRTI mutation E138K with the NRTI mutation M184I. Eighty percent of subjects used emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF); a single tablet regimen of FTC/RPV/TDF is in development. METHODS HIV-1 with E138K and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

The prevalence of E138K mutation and other polymorphisms prior to ETR usage in a drug-experienced cohort failing on M1841/V-inducing NRTI regimens

C Loveday, E. MaCrae
Antivir Ther • 2011
View 7 Excerpts
Highly Influenced

The prevalence of E 138 K mutation and other polymorphisms prior to ETR usage in a drug - experienced cohort failing on M 1841 / V - inducing NRTI regimens . [ abstract 49 ]

C Loveday, E MaCrae
Antivir Ther • 2011

Similar Papers

Loading similar papers…